FindTrial
Sign In

Gonadotropin-releasing hormone (GnRH) agonist for prevention of chemotherapy induced menopause in malignant ovarian germ cell tumor: a multicenter study

Gonadotropin-releasing hormone (GnRH) agonist for prevention of chemotherapy induced menopause in malignant ovarian germ cell tumor: a multicenter study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0003286
Enrollment
65
Registered
2018-10-25
Start date
2018-10-22
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Bundang CHA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed as pathologically malignant germ cell tumors of the ovary. Patients who received at least one ovarian conserved chemotherapy 2) Patients 12 years old (after menarche) ~ 40 years old

Exclusion criteria

Exclusion criteria: 1) Post menpausal women 2) Premenstrual girl 3) Patients with menopause induced by surgery or radiation therapy prior to chemotherapy 4) Patients diagnosed with other carcinoma and underwent chemotherapy and pelvic radiation therapy

Design outcomes

Primary

MeasureTime frame
The incidence of early menopause induced by chemotherapy—

Secondary

MeasureTime frame
Age of menopause, pregnancy rate and side effects of GnRH agonist—

Countries

Korea, Republic of

Contacts

Public Contactmin choi

Bundang CHA General Hospital

oursk@hanmail.net+82-31-780-6191

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026